文献速递生殖医学妇科

线粒体功能障碍与遗传学在女性不孕及早发性卵巢功能不全中的作用

The role of mitochondrial dysfunction and genetics in female infertility and premature ovarian insufficiency.
PubMed 文献 · Hum Reprod Update · 2026-08-19

本综述总结线粒体相关基因及变异在早发性卵巢功能不全(POI)中的作用,指出线粒体疾病女性应监测POI,而看似孤立的POI患者可能携带线粒体疾病相关基因的致病变异。

要点

  • 线粒体疾病女性应监测POI,以便早期发现并启动激素替代治疗。
  • 孤立性POI患者可能携带线粒体疾病相关基因致病变异,需监测相关临床表现。
  • 线粒体补充或线粒体捐赠可能是未来线粒体相关不孕的治疗方向。

核心结论

  • 线粒体基因/蛋白变异可负向影响卵巢功能,卵巢储备对线粒体功能障碍具有广泛敏感性。
  • 线粒体功能障碍与不孕可单独出现或作为综合征一部分,不孕可能是线粒体疾病的首个临床征象。

研究设计与样本

  • 综述:检索PubMed数据库截至2026年3月的英文文献,关键词包括POI、线粒体、线粒体DNA、遗传学、辅助生殖技术等。

主要发现

  • 女性不孕发生于约37%的不孕夫妇中,POI影响1-3.7%的40岁以下女性。
  • 多种线粒体通路与女性不孕相关,反映卵巢储备对线粒体功能障碍的广泛敏感性。

临床怎么用

  • 线粒体疾病女性应监测POI,以便早期发现并及时给予激素替代治疗,降低心血管和骨骼疾病等共病风险。
  • 表现为孤立性POI的女性应关注线粒体疾病相关基因致病变异,根据遗传病因监测听力损失、视力障碍、心肌病、肌无力和神经退行性变。
  • 未来线粒体相关不孕的治疗可能包括线粒体补充或线粒体捐赠以优化生殖成功概率。
  • 生物标志物作为POI早期诊断工具目前临床效用有限,但早期筛查方法的进一步发展对POI检测、诊断和早期干预具有重要价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Female infertility occurs in ∼37% of infertile couples, while premature ovarian insufficiency (POI) impacts 1-3.7% of women under the age of 40. POI is clinically heterogeneous, with various genetic pathways associated with its pathogenesis. Mitochondrial diseases (MDs) are a broad group of clinically heterogeneous genetic conditions characterized by aberrantly functioning mitochondria. MDs have a disproportionate burden on organs and tissues with increased aerobic/energy demands, such as the heart, skeletal muscles, brain, and ovaries. The role of mitochondria in female fertility and ovarian reserve is increasingly being recognized. OBJECTIVE AND RATIONALE: A comprehensive understanding of the role of mitochondria in the maintenance of female fertility is pertinent to better understanding female reproductive potential. In a world with increasing demand for assisted reproductive technologies (ART), due to a considerable rate of global infertility, there is a need to better understand the genes and pathways involved in female reproduction. This review summarizes, evaluates, and explores the current knowledge of mitochondria-associated genes and variants that are implicated in POI, including their function and dysfunction in female reproduction. SEARCH METHODS: We searched articles in the PubMed database, containing the following key words: premature ovarian insufficiency, mitochondria, mitochondrial, premature ovarian failure, genetics, mitochondrial DNA, mtDNA, mitochondrial protein, infertility, premature menopause, mitochondrial donation, assisted reproductive technologies, electron transport chain, oxidative phosphorylation (OXPHOS), mitochondrial disease, oocyte, oogenesis, meiosis, in vitro fertilization, mitoribosome, Perrault syndrome, and ovarioleukodystrophy, in the English-language literature until March 2026. OUTCOMES: Genetic variants that affect mitochondrial genes/proteins can negatively impact ovarian function. Various mitochondrial pathways are associated with female infertility, reflecting the broad sensitivity of ovarian reserve to mitochondrial dysfunction. Mitochondrial dysfunction and infertility can present in isolation or as part of a syndrome. Infertility in women may be the first clinical sign of a MD. Conversely, POI may be an underappreciated symptom of MDs. WIDER IMPLICATIONS: This review draws attention to the fact that females with MDs should be monitored for POI so it can be detected early for prompt and appropriate therapeutic interventions, such as hormone replacement therapy. This is known to mitigate the risk of comorbidities such as cardiovascular and bone disease and will optimize long-term health outcomes. Of equal importance, our review highlights the potential for girls and women presenting with apparently 'isolated' POI to harbour pathogenic variants in MD-associated genes, therefore putting these individuals at risk of developing further clinical manifestations of MDs. We emphasize the need for surveillance in these cases for hearing loss, vision disturbance, cardiomyopathy, muscle weakness and neurodegeneration, depending on the genetic cause. Given that mitochondrial function is essential to female fertility, future therapies for mitochondria-associated infertility could involve mitochondrial supplementation to improve the mitochondrial fraction or mitochondrial donation to optimize the likelihood of reproductive success. Finally, we also discuss the current landscape of biomarkers as potential early diagnostic tools for POI. Whilst currently rudimentary in their clinical utility, the further development of early screening methods will be invaluable for the detection, diagnosis, and early intervention of POI. REGISTRATION NUMBER: N/A.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Kline BL, Compton AG, Frazier AE, et al. The role of mitochondrial dysfunction and genetics in female infertility and premature ovarian insufficiency. Hum Reprod Update. 2026. PMID: 42616676. doi:10.1093/humupd/dmag022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。